INSM250117C70000
- 4.85
- 0.000.00%
Insmed Newsroom
Insmed Is Maintained at Overweight by JP Morgan
Insmed Analyst Ratings
J.P. Morgan Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $83
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Truist Financial Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $105
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $75 to $105
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $85 to $105
Insmed Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Insmed Analyst Ratings
Mizuho Securities Maintains Insmed(INSM.US) With Buy Rating
BofA Securities Maintains Insmed(INSM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)
Insmed Price Target Raised to $100.00/Share From $85.00 by Truist Securities
Truist Financial Maintains Insmed(INSM.US) With Buy Rating
Insmed Analyst Ratings
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $75 to $98
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Verona Pharma (VRNA) and Hims & Hers Health (HIMS)
TD Cowen Sticks to Its Buy Rating for Insmed (INSM)
Brensocatib Shows Broad Efficacy in NCFB Subpopulations, Justifying Buy Rating for Insmed